



Data Redaction Solution





Book a Free Demo at

gramener.com/demorequest



Clinical Trials Transparency: Redaction & Anonmyzation of patient personal information and company confidential information



Problem

- Client had a need to protect content such as intellectual property and personally identifiable information in clinical trial documents that are shared with third parties including health authorities and partners
- Anonymization of clinical summary reports is a regulatory requirement for EMA and health Canada
- Regulatory requirements have been growing over the recent years and other country health authorities are expected to follow suit leading to an increased demand for reduction and anonymization solutions



Approach

- The standard approach was to outsource to vendors the anonymization and redaction of patient personally identifiable information
- 3rd party vendors were taking longer time, were expensive and yet not delivering good accuracy of the documents
- Also 3rd party vendors were not delivering an assessment of risk of re-identification of data



Outcome

- Gramener developed a custom platform for redaction and anonymization for the client, leveraging NLP and other Al/ ML technologies
- The relevant PharmaCo personnel can now cater to requests for clinical trial information from outside quickly and more accurately and with the option for a Human to quickly validate the results from the Al/ ML enabled platform
- This has resulted in 97% time savings in submission process and expected to deliver savings of \$1mn pa



Case Study: We delivered for a Big PharmaCo, their internal platform for Analytics driven automation of Risk Anonymization, with significant time & cost savings

Redaction & Risk based anonymization are manual and high TATactivities which require iterative risk computation to be in compliance with EMA & HC norms. This delays regulatory submissions and increases the time to market

Privacy AI combines key elements of

- Al algorithms to identify required entities
- Risk computation algorithms
- Human in the loop interface to allow users to control the process


Solution cuts down process turn around times and still ensures risk of patient reidentification is under the regulatory thresholds of 0.09




Time Savings in submission process


\$1M/year

Cost Savings for only 1 use-case





Review model output using statistical sampling



Compare original and anonymized files, download submission ready packages

Clinical trials transparency regulation implies that Pharma companies face the prospect of millions of dollars in risks and costs from any lapses in compliance

Regulatory changes relevant for Pharma Industry

The regulatory framework is evolving...

... to support better, faster, cheaper innovation in medicines for patients...

...while protecting privacy of patients and confidential data

US FDA, Europe's EMA, 'Health Canada' have mandated clinical trial data transparency

(as it is a lever to reduce ecosystem level R&D costs)

GDPR for data protection requires that patient related and other confidential data needs to be protected

Implication for Pharma companies

High penalties for non-compliance or for errors

Default methods to hide patient data are...

...manual, time-consuming, errorprone, non-standard & expensive

Currently available softwares are expensive, provide low accuracy and **do not** enable End-to-end automation

Financial Impact

Errors could result in law-suits with liabilities running into millions of dollars

Delays could risk penalties of \$0.3 mn monthly

pepending on scale, spend of \$2-3 mn pa in external vendor costs are incurred in addition to internal Org costs



To avoid and minimize financial risk of clinical trial transparency non-compliance, Gramex-4-Health Offers the most promising new technology for pharma companies


Options for Pharma Companies Leverage services Consider Maintain inhouse from CROs and other Gramex-4-Health teams to carry out regulatory service (G4H) redaction providers Use of Tools & Technology Use Adobe or similar This is the most common tool for manual redaction efforts too Significantly more powerful than Leverage available Currently available tools in the market are available tools AI/ML enabled software unable to maximize end-to-end automation Expertise to help you cost Potential option for companies spending >1mn effectively build & maintain Create internal AI/ ML pa with external service providers for redaction inhouse platform based platform & anonymization or redact as a service

Gramex-4-Health (G4H) 'Redaction & Anonymization' Platform is custom built for each client's needs

Problem solved by G4H Tool

Automate the masking/ redaction/ anonymization of private, sensitive & confidential information in several large business critical documents, before sharing with 3rd parties

(e.g. clinical trial results sharing with 3rd parties as mandated by regulators in US, Europe, Canada)



Most accurate, fast, cost-effective and automated approach to protect against regulatory penalties running into millions of dollars

G4H Custom Platform for redaction & Anonymization is targeted to offer significant benefits over other options

Detailed list of G4H Platform Features

- Automated deidentification
- 2. Integrated re-identification risk measurement and reporting
- 3. PHI leak rate calculation
- 4. Full submission package
- 5. Automated compliance report generation
- 6. Active learning module
- 7. Management Portal
- 8. User centered UI
- 9. Deep Learning, NLP Module
- 10. Integration & Automation within the pipeline
- 11. Auditable logs
- 12. Submission Status
- 13. Deployable on-prem or in the cloud
- 14. Human in the loop Validation
- 15. Data-identification APIs
- 16. Reusable Template
- 17. Guidable Process workflow
- 18. Single Platform for all the services

G4H Differentiators compared with competitors

Accuracy

90%+ accuracy (10-20% points better than alternatives)

Speed

90% faster

End-to-end automation

70% more automation

Cost

40% of cost of alternatives

Continuous Improvement

Human in the Loop

